Skip to search formSkip to main contentSkip to account menu

AC-T Regimen

Known as: AC-T, AC-Taxol Regimen 
A chemotherapy regimen consisting of doxorubucin hydrochloride (Adriamycin) and cyclophosphamide, followed by paclitaxel (Taxol), administered on… 
National Institutes of Health

Related topics

Related topics

4 relations
CyclophosphamideDoxorubicinPaclitaxelinvasive breast cancer

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study
Background The breast cancer chemotherapy leads to diverse aspects of noxious or unintended adverse drug reactions (ADRs) that… 
2020
2020
Assessing the Effects of Redox Modifier MnTnBuOE-2-PyP 5+ on Cognition and Hippocampal Physiology Following Doxorubicin, Cyclophosphamide, and Paclitaxel Treatment
Background: Chemotherapy treatment for breast cancer can induce cognitive impairments often involving oxidative stress. The brain… 
Review
2017
Review
2017
Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer
PurposeThe Oncology Care Model was developed, in part, to reduce acute care use during the 6 months after chemotherapy initiation… 
2015
2015
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in…
The N9831 trial demonstrated the efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2… 
2013
2013
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting
Early-stage breast cancer (ESBC) is commonly treated with myelosuppressive chemotherapy, and maintaining full-dose chemotherapy… 
Highly Cited
2012
Highly Cited
2012
Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice
Chemotherapy is widely used to treat early stage breast cancer (ESBC). Reductions and delays in dose administered—e.g., due to… 
2011
2011
Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: A phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with…
553 Background: Trastuzumab-chemotherapy-based adjuvant therapy (AC-TH or TCH) provide significant improvement in disease-free… 
Highly Cited
2009
Highly Cited
2009
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
PURPOSE To assess whether trastuzumab (H) with radiotherapy (RT) increases adverse events (AEs) after breast-conserving surgery… 
2009
2009
Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer
Introduction The objective of this study was to examine the feasibility and toxicity of adjuvant dose-dense chemotherapy in older… 
2005
2005
Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy
SummaryObjective. To retrospectively determine the relationship of age to toxicity from adjuvant chemotherapy for breast cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)